At Cambridge Medical Group, Dr Lee Mun Heng, its founder, has always sought to introduce the latest and newest in medical aesthetic innovations to his patients.
In fact, Dr Lee’s strong interest in research-based medicine came about when he was studying at the University of Cambridge where he did a stint at its research department. Dr Lee, who has been practising aesthetic medicine for almost 10 years, has also completed training in facial sculpting, pigmentation disorders and laser technology with leading experts in Japan, South Korea and even Italy.
“New innovations with a clinical application have always caught my interest,” says Dr Lee.
This is why the Cambridge Medical Group recently embarked on a partnership with another homegrown company, CellResearch Corp, to conduct clinical trials that will help shape the future of aesthetic medicine in Singapore.
Bio-tech company CellResearch Corp was founded in 2002 by plastic surgeons and individuals with an active interest in the life sciences sector. It is known for being the first in the world to discover a rich source of epithelial and mesenchymal stem cells in the umbilical cord lining.
These cells are currently being developed to treat a wide range of diseases including those of the brain, heart, skin and cornea. To maximise the future use of cord lining stem cells, CellResearch Corp believes that the membrane from which the cells are derived should be “banked”.
Just last year, the company also signed a research agreement with a top US university hospital to use these cells in wound care clinical trials. “This wound-healing application will be ready for consumers in about three to five years”, reveals Gavin Tan, CellResearch Corp’s founding director and CEO.
In the meantime, to make its technology more accessible to the general public, CellResearch Corp has created Calecim, which harnesses the same advanced stem cell technology, for use only in doctors’ clinics as an anti-ageing and post-procedure recovery skincare line. One of these clinics in Singapore is the Cambridge Medical Group. Calecim is a protein-rich formulation of nutrients that sends “youth signals” to skin to make it act and look younger.
In a recent clinical trial in San Francisco, it was found that patients had firmer and more lifted and elastic skin, and fewer signs of pigmentation and fine lines, after using the Calecim Multi-Action Cream for only two weeks.
In another trial done by an Orange County dermatologist, all the patients reported less pain, swelling and redness after the Calecim serum was administered on their skin after an invasive laser procedure. “This results in overall patient satisfaction, which is an important factor if patients are to return for repeat procedures,” says Tan.
CellResearch Corp’s latest collaboration with Cambridge Medical Group will mean that the latter can conduct clinical observations that determine the positive effects of Calecim products on Asian skin, in particular. So far, initial observations have shown encouraging results.
Says Dr Lee: “In our day-to-day practice, we often deal with patients with acne scars, open pores, fine lines and sun damage. They require fractional lasers or nano-radiofrequency treatments which mean healing time is always a concern. And patients now want a quicker healing time. It will be wonderful if healing technology (from CellResearch Corp) can be used to improve patient outcome.”
“I believe that this collaboration will be both scientifically challenging and fulfilling. We also hope that this collaboration will start a new wave of evidence-based medicine in Singapore’s aesthetic medicine industry. It’s not about making money. We want to leave knowing that we cared and we have helped.”
#08-05A2 Tower B, Ngee Ann City; Tel: 6733 6729; cambridgetherapeutics.com.sg